Phaedre Mohr
Overview
Explore the profile of Phaedre Mohr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Khan M, Sokoll L, Chan D, Mangold L, Mohr P, Mikolajczyk S, et al.
Urology
. 2004 Dec;
64(6):1160-4.
PMID: 15596190
Objectives: To investigate the clinical utility of the subforms of free prostate-specific antigen (PSA), namely proPSA and "benign" PSA (BPSA), to improve cancer detection when the percent free PSA level...
12.
Sokoll L, Chan D, Mikolajczyk S, Rittenhouse H, Evans C, Linton H, et al.
Urology
. 2003 Feb;
61(2):274-6.
PMID: 12597929
Objectives: To determine the clinical utility of using proenzyme prostate-specific antigen (pPSA) for early detection of prostate cancer in the 2.5 to 4.0 ng/mL total PSA range. pPSA, the precursor...
13.
Sokoll L, Bruzek D, Dua R, Dunn W, Mohr P, Wallerson G, et al.
Urology
. 2002 Oct;
60(4 Suppl 1):24-30.
PMID: 12384159
Differences in stability of the free and complexed molecular forms of prostate-specific antigen (PSA) may influence the clinical utility of assays for these forms, as well as the calculated ratios...
14.
Sokoll L, Mangold L, Partin A, Epstein J, Bruzek D, Dunn W, et al.
Urology
. 2002 Oct;
60(4 Suppl 1):18-23.
PMID: 12384158
Over time, the parameters commonly used to predict pathological stage in men with localized prostate cancer have changed, and there is now little stratification in pretreatment prostate-specific antigen (PSA) concentrations,...